After three brushes with cancer, Robert Weker understands the patient journey more than many – and he is determined to put that experience to good use.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh